So­bi bets $250M cash, about $1B in mile­stones for rights to a C3 ther­a­py be­ing pushed through 5 piv­otal tri­als

A cou­ple years af­ter li­cens­ing Novim­mune’s ema­palum­ab and turn­ing around a quick FDA OK, Stock­holm-based So­bi is bet­ting up to $1.2 bil­lion for rights to an­oth­er rare dis­ease drug.

The com­pa­ny is shelling out $250 mil­lion up­front and adding up to $915 mil­lion in mile­stones for rights to de­vel­op and com­mer­cial­ize Apel­lis Phar­ma­ceu­ti­cals’ drug pegc­eta­coplan out­side the US. To­geth­er, the com­pa­nies will see the sys­temic C3 ther­a­py through five reg­is­tra­tional tri­als in hema­tol­ogy, nephrol­o­gy and neu­rol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER